Biopharma Co Vyome gets Rs 154 crore from investors

New Delhi: Vyome Therapeutics, a biopharmaceutical firm focused on developing dermatology products, has raised $22 million (about Rs 154 crore) in a fresh round of funding led by Mumbai based venture growth fund Iron Pillar to expand its team and further invest in research and development.

Existing investors Perceptive Advisors, Romulus Capital and Kalaari Capital also participated in this round. Part of the funds are being used for a secondary transaction, the company said without elaborating. Prior to this round, the company had raised about $30 million from Perceptive Advisors, Romulus Capital, Kalaari Capital, Sabre Partners India, Aarin Capital and Navam Capital.

Dermatological conditions are among the most common types of disorders globally and a majority of the market share is held by large pharmaceutical firms with established product lines. However, with the emergence of a number of startups which have proven clinical and commercial success along with d eep understanding of many dermatological conditions, there is a renewed investor interest in disruptive companies in this segment.

  • Related Posts

    Diabetic drug metformin found to act on brain

    NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

    Hetero debuts semaglutide generic in emerging markets

    New Delhi: Hyderabad-based drugmaker Hetero has announced the launch of its generic semaglutide portfolio in emerging international markets. In a phased global push, the company plans to roll out its…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework